scholarly journals Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes

2013 ◽  
Vol 94 (11) ◽  
pp. 2504-2514 ◽  
Author(s):  
Fang Zhou ◽  
JieZhong Chen ◽  
Kong-Nan Zhao

Human papillomavirus 16 (HPV16) infection causes 50 % or more of cervical cancers in women. The HPV16 E7 oncogene is continuously expressed in infected epithelium with its oncogenicity linked to cervical cancer. The E7 protein is an ideal target in control of HPV infection through T-cell-mediated immunity. Using HPV16 E7-transgenic mouse keratinocytes (KCs–E7) to investigate T-cell-mediated immune responses, we have shown previously that HPV16-encoded E7 protein inhibits IFN-γ-mediated enhancement of MHC class I antigen processing and T-cell-induced target cell lysis. In this study, we found that HPV16 E7 suppresses IFN-γ-induced phosphorylation of STAT1(Tyr701), leading to the blockade of interferon regulatory factor-1 (IRF-1) and transporter associated antigen processing subunit 1 (TAP-1) expression in KCs–E7. The results of a 51Cr release assay demonstrated that IFN-γ-treated KCs–E7 escaped from CTL recognition because HPV16 E7 downregulated MHC class I antigen presentation on KCs. Restoration of IRF-1 expression in KCs–E7 overcame the inhibitory effect of E7 protein on IFN-γ-mediated CTL lysis and MHC class I antigen presentation on KCs. Our results suggest that HPV16 E7 interferes with the IFN-γ-mediated JAK1/JAK2/STAT1/IRF-1 signal transduction pathway and reduces the efficiency of peptide loading and MHC class I antigen presentation on KCs–E7. These results may reveal a new mechanism whereby HPV16 escapes from immune surveillance in vivo.

2007 ◽  
Vol 180 (1) ◽  
pp. 372-382 ◽  
Author(s):  
Andreas Goldwich ◽  
Sabine S. C. Hahn ◽  
Sandra Schreiber ◽  
Stefanie Meier ◽  
Eckhart Kämpgen ◽  
...  

2006 ◽  
Vol 36 ◽  
pp. S17-S18
Author(s):  
A.J. Gehring ◽  
P.T.F. Kennedy ◽  
D. Sun ◽  
E. Nolte-'t Hoen ◽  
S. Lim ◽  
...  

2006 ◽  
Vol 104 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Eiji Satoh ◽  
Tadashi Mabuchi ◽  
Hiroki Satoh ◽  
Takayuki Asahara ◽  
Hideaki Nukui ◽  
...  

Object It remains unclear whether malignant glioma cells can deliver tumor antigens efficiently to major histocompatibility complex (MHC) Class I molecules. To elucidate the mechanism of antigen presentation in malignant gliomas, the authors examined the expression of the transporter associated with antigen processing 1 (TAP1), which transports antigens to MHC Class I molecules, and low-molecular-mass polypeptide 2 (LMP2), which is a subunit of a proteasome. They also analyzed the effects of interferon (IFN)-γ and IFN-β on the expression of these molecules. Methods Five glioma cells expressed undetectable or very low levels of TAP1 protein and did not express TAP1 messenger (m)RNA. Normal brain tissue and glioma tissue specimens also showed undetectable levels of TAP1 protein and the same levels of LMP2 protein as lymphoblastoid B cells. Treatments of the tumor cells with IFN-γ or -β enhanced the expression of both TAP1 protein and mRNA as well as the expression of MHC Class I molecules. The expression of LMP2 protein was not altered by the IFN treatments. The authors analyzed structural alterations in the TAP1 promoter region in eight malignant glioma cell lines. Single nucleotide polymorphism was found in 446 bp upstream of the translation start site of the TAP1 gene, and a point mutation was found in 34 bp upstream of the TAP1 gene. Conclusions Malignant glioma cells may be less immunogenic due to low levels of TAP1 expression. Upregulated expression of TAP1 and MHC Class I molecules by IFN-γ and -β may enhance antigen presentation in malignant glioma cells.


2007 ◽  
Vol 179 (11) ◽  
pp. 7614-7623 ◽  
Author(s):  
Gina M. Doody ◽  
Sophie Stephenson ◽  
Charles McManamy ◽  
Reuben M. Tooze

Sign in / Sign up

Export Citation Format

Share Document